Loading...
•
Dec 31, 2025
•/
GSK Q4 2025 Earnings Report
GSK reported strong fourth-quarter performance driven by Specialty Medicines growth.
Key Takeaways
GSK delivered solid Q4 2025 results with revenue growth led by Specialty Medicines, higher operating profit, and strong cash generation.
Specialty Medicines continued to drive revenue growth
Operating profit increased significantly year over year
Strong cash generation supported shareholder returns
US and Europe both delivered solid quarterly revenue growth
Revenue by Geographic Location
Forward Guidance
GSK reaffirmed its outlook for 2026 with expectations for continued growth in revenue, operating profit, and earnings.
Positive Outlook
- Expected turnover growth of 3% to 5%
- Core operating profit growth expected at 7% to 9%
- Core EPS growth expected at 7% to 9%
- Specialty Medicines expected to grow at a low double-digit rate
- Strong pipeline and R&D momentum
Challenges Ahead
- Vaccines expected to be flat to slightly down
- General Medicines expected to be flat to slightly down
- Foreign exchange headwinds may impact reported growth
- Higher R&D investment may pressure margins
- Macroeconomic and regulatory uncertainties
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...